成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Infectious disorders drug targets >>article

Infectious disorders drug targets

Download PDF

Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?

Published:1 January 2020 DOI: 10.2174/1871526518666180816101124 PMID: 30113002
Deepti Chopra, Bharti Bhandari

Abstract

Chronic hepatitis C remains a major public health concern with a prevalence of more than 1% worldwide. Of late, with the discovery of newer drugs, chronic HCV treatment has touched new dimensions. The treatment has progressed from Interferons to Pegylated interferon (Peg IFN) based therapy, with or without ribavirin to treatment with orally active Direct Acting Antivirals (DAA) with Peg IFN and ribavirin and eventually to various combinations of DAA, without IFN. Introduction of newer DAAs has transfigured the treatment of chronic HCV. Chronic HCV patients with advanced liver disease, psychiatric condition, anemia or autoimmune diseases, not eligible for Peg IFN based therapy have a ray of hope now. Amongst all DAAs, nucleoside inhibitors have been the most promising agent. Thus the present review focuses on Sofosbuvir, one of the most effective nucleoside inhibitors; in terms of potency, resistance profile, activity against all genotypes of HCV and adverse effects. FDA approved Sofobuvir for clinical use in 2013. Chemically, it is 2'-deoxy-2'-α-fluoro-β-Cmethyluridine- 5'-triphosphate; a phosphoramidate prodrug that is activated by enzyme present in human liver. It is a highly potent inhibitor of HCV NS5B polymerase. Efficacy of the Sofosbuvir has been established in various phase 2 and phase 3 clinical trials like PROTON, ELECTRON, FUSION, POSITRON etc. Sofosbuvir has a good safety profile with few mild to moderate adverse effects. Evidence reveals that sofosbuvir has substantial impact on the treatment of HCV.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Sofosbuvir 1190307-88-0 C22H29FN3O9P 582 suppliers $50.00-$3990.00
2'-O-Methyl-5-methyluridine 5'-triphosphate triethylammonium salt 444789-41-7 C11H19N2O15P3 7 suppliers Inquiry

Similar articles

IF:4.6

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

Clinical Pharmacokinetics Brian J Kirby, William T Symonds,etc Published: 1 July 2015
IF:1.3

Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature.

Acta gastro-enterologica Belgica A Roussos, S Koilakou,etc Published: 1 January 2008
IF:0

C-Arylglucoside synthesis: triisopropylsilane as a selective reagent for the reduction of an anomeric C-phenyl ketal

Tetrahedron, asymmetry B. Ellsworth,?A. Doyle,etc Published: 17 October 2003